Suzy Too (Suzy Q BX1): A Comprehensive Strain Guide

Introduction to Suzy Too (Suzy Q BX1)

Suzy Too, often labeled as Suzy Q BX1, is a CBD-forward cultivar bred to capture the calm, clear-headed personality of the original Suzy Q while improving consistency. The BX1 tag indicates a first backcross, a breeding technique used to lock desired traits and reduce variability across plants.

As a result, Suzy Too tends to showcase a reliable high-CBD, low-THC chemotype with a gentle, earthy aroma and smooth, non-intoxicating effects. For consumers seeking relief without heavy euphoria, it occupies a sweet spot in the modern cannabis landscape.

Because the public record on niche CBD cultivars is sometimes thin, much of what is known about Suzy Too comes from breeder notes, grower observations, and aggregated lab results from Suzy Q-type lines. Still, the picture that emerges is consistent: Suzy Too is built for clarity, calm, and functional daytime use.

This profile integrates what’s known about the Suzy Q family with the specific intent behind a BX1 release. Where possible, data ranges are provided to ground expectations in numbers rather than hype.

History and Naming

Suzy Q rose to prominence during the mid-2010s CBD renaissance in Northern California, when patients and caregivers demanded non-intoxicating flower with therapeutic promise. Early cuts of Suzy Q earned a reputation for CBD percentages that competed with THC cultivars in sheer cannabinoid content.

As demand grew, breeders sought to stabilize Suzy Q’s chemotype and horticultural behavior. The BX1 designation on Suzy Too signals the first step toward that goal: backcrossing into the original Suzy Q line to fix the high-CBD trait.

Backcrossing is a standard method in cannabis breeding to reduce off-type phenotypes and increase the frequency of the target chemotype. On average, a BC1 population retains roughly 75% of the recurrent parent’s genome, making it feel like “Suzy Q—too,” hence the playful naming.

The naming also communicates intent to consumers and cultivators. Where the original Suzy Q could vary in THC drift between phenotypes, Suzy Too aims to rein in those outliers for a more predictable CBD:THC ratio.

In practice, that means tighter clustering around CBD-dominant outcomes in lab tests. Growers report fewer surprises at harvest, less anxiety over late-flower THC creep, and better uniformity plant-to-plant compared with unworked Suzy Q seed populations.

Suzy Too’s emergence parallels the push for precise, data-backed cannabinoid profiles that comply with medical program requirements. It also caters to adult-use customers who want functional flower for daytime without overwhelming intoxication.

While specific trophy-list histories can be murky for CBD cultivars, consumer adoption remains the relevant metric. In budtender feedback and patient boards, Suzy Too-type phenotypes commonly score high for consistency, smoothness, and dependable CBD relief.

Genetic Lineage and Breeding Logic

Genetically, Suzy Too is best understood as a Suzy Q backcross that emphasizes a CBD-dominant chemotype. In cannabis chemistry, the CBD-dominant profile arises from functional CBDAS (cannabidiolic acid synthase) and either a non-functional or reduced-activity THCAS.

At the Bt:Bd locus, CBD-dominant plants typically carry Bd/Bd alleles, steering the precursor CBGA toward CBDA formation. The BX1 breeding step increases the probability that offspring inherit the Bd/Bd state and express CBD as the principal cannabinoid.

On average, a BC1 population inherits around 75% of the recurrent parent’s genome. With selective pressure, breeders can push that number higher for key trait blocks associated with cannabinoid ratio, aroma, and plant structure.

Because early CBD lines often arose from polyhybrid backgrounds, locking the chemotype can take multiple generations. BX1 is a foundational step, but further selection within the BX1 pool is common to tighten the CBD range and limit THC variability.

From a cultivar management perspective, growers should still phenotype Suzy Too to find their preferred expressions. Even within a stabilized pool, minor drift in terpene balance, stretch, and bud density is normal in seed runs.

A core breeding target in the Suzy Q family has been to combine CBD potency with good agronomics. That includes reasonable internode spacing, moderate stretch in flower, and trichome density sufficient for hash or rosin while maintaining low THC.

Compared with many hemp-type cultivars, Suzy Too usually carries more resin and richer terpene layers. This positions it as a craft CBD cultivar rather than a pure fiber or biomass type, suitable for connoisseur-grade flower and solventless extraction.

Appearance and Structure

Suzy Too often presents medium-tall plants with a balanced, slightly sativa-leaning structure. Expect internode spacing to be moderate, with a 1.5x to 2.0x stretch after flip in most environments.

Buds tend toward conical spears with a calyx-forward look, not overly airy but typically less rock-hard than high-THC indica-leaning varieties. The bract-to-leaf ratio is favorable, making trimming straightforward and efficient.

Coloration runs lime to forest green with orange to rust pistils that darken as harvest nears. Under optimal nutrition and light intensity, trichomes present as a bright, frosty sheen despite the cultivar’s low THC.

Growers note that CBD-dominant resin heads can still be abundant and sticky. Under 60x loupe, heads often show well-formed capitate-stalked trichomes, with cloudy maturation arriving slightly earlier than in many THC cultivars.

In a jar, Suzy Too’s bag appeal is understated and clean. Buds hold their shape, cure evenly, and break down with a resinous, not crumbly, texture if dried at proper humidity.

Stems are medium in thickness and benefit from light trellising once colas build weight. Support also helps maintain an even canopy for improved light distribution and airflow.

Leaf morphology is typically narrow-to-medium leaflets with a subtle serration pattern. Fan leaves respond well to selective defoliation, which improves airflow and lowers botrytis risk in dense parts of the canopy.

Aroma Profile

Aromatically, Suzy Too leans earthy-woody with light floral and citrus-pine lifts. Many growers describe initial notes of cedar, fresh soil, and wild herbs when the jar is first cracked.

Secondary layers often include black pepper, lemongrass, and faint sweetness reminiscent of chamomile or honey tea. The profile is gentle but complex, not aggressively gassy or skunky.

Pinene-driven pine and caryophyllene-driven spice commonly appear after a grind. This intensifies the woody edges while keeping the bouquet refined and approachable.

During cure, the top end tends to round off slightly, letting soft herbal tones come forward. If drying is too fast, citrus and floral high notes diminish by 20–30% based on typical terpene volatility measurements.

In the room, flowering plants give off a pleasant, moderate aroma density. It’s noticeable but not the kind of nose-tingling intensity associated with high-myrcene, high-mercaptan fuel cultivars.

For consumers sensitive to pungency, Suzy Too often strikes the right balance. It remains aromatic enough for connoisseurs yet manageable for discreet storage and use.

Flavor Profile

The flavor follows the nose with clean earth, gentle wood, and a lightly sweet finish. A peppery tickle often appears on the exhale, balancing the herbal tea impression.

On vaporization, pine and citrus lift at lower temperatures, while the resin’s wood-spice core shows at higher temperatures. Most users find the smoothest flavor between 175 and 190°C on a dry herb vaporizer.

Combustion is typically easy on the throat if the flower is cured at 58–62% relative humidity. Over-dried samples can taste sharper, with pepper dominating and herbal sweetness receding.

Aftertaste is mild and pleasant, lingering as a clean, cedar-tea echo. For edibles and tinctures, the profile infuses as a grassy-honey note that blends well with citrus, chocolate, or baking spices.

Cannabinoid Profile

Suzy Too is designed to be CBD-dominant, with common lab ranges showing CBD around 10–18% by dry weight. THC typically falls between 0.3–4.0%, producing CBD:THC ratios from roughly 5:1 up to 20:1 depending on phenotype and cultivation conditions.

At 15% CBD, each gram of flower carries approximately 150 mg CBD. At 1% THC, each gram would contain about 10 mg THC, usually below a threshold that produces pronounced intoxication for most users.

Minor cannabinoids may include CBG in the 0.3–1.0% range and CBC around 0.2–0.6%. These values vary widely by environment, harvest timing, and specific selection within the BX1 pool.

Total cannabinoid content for well-grown samples commonly lands in the 12–20% range, dominated by CBD. This aligns with the qualitative goal of a calming, functional experience rather than a heavy psychoactive impact.

Decarboxylation efficiency for CBD and THC typically ranges from 70–90% depending on method and time-temperature profiles. In smoking and vaping, rapid decarb and delivery yield a fast onset but with some loss to thermal degradation.

Lab variability should be considered when interpreting results. Inter-lab differences can produce ±1–2 percentage points absolute for cannabinoids and 10–20% relative variance due to differing methods and calibration.

For compliance contexts, note that delta-9 THC must remain under jurisdictional limits. While some Suzy Too phenotypes may approach hemp thresholds, many will exceed 0.3% THC, making this primarily a high-CBD cannabis cultivar rather than a hemp variety.

In extracts, Suzy Too can yield CBD-rich oil efficient for formulation. Solventless rosin from well-cured flower often lands in the 55–70% total cannabinoid range, with CBD dominance preserved.

Terpene Profile

Suzy Too’s terpene total often falls between 1.5–2.8% by weight in well-grown indoor flower. Outdoor-grown samples may show slightly lower totals due to environmental stress and higher volatilization.

Dominant terpenes are frequently beta-caryophyllene, alpha-pinene, and myrcene. Subdominant contributors commonly include humulene, bisabolol, and linalool.

Representative distributions might look like 0.25–0.60% beta-caryophyllene, 0.10–0.30% alpha-pinene, and 0.30–0.80% myrcene. Humulene often sits at 0.08–0.20%, with bisabolol and linalool each in the 0.05–0.15% range.

Caryophyllene imparts spice and wood, pinene adds pine and cognitive clarity, and myrcene brings gentle herbality. Bisabolol contributes a sweet, chamomile-like softness that many users notice in the finish.

Terpene expression is highly environment-dependent. High-intensity light, balanced nutrition, and careful post-harvest handling can preserve 70% or more of native terpene content compared with careless drying.

Drying at 60°F and 60% RH for 10–14 days is a widely adopted standard for preserving fragile monoterpenes. Rapid drying at higher temperatures can strip 20–40% of the top-end aromatics, flattening flavor.

When vaporized at stepped temperatures, pinene and limonene pop first below 185°C, while caryophyllene and humulene become more evident above 195°C. This makes Suzy Too an excellent candidate for session-style vaping that explores the flavor arc.

From a pharmacologic standpoint, beta-caryophyllene is a CB2 receptor agonist with anti-inflammatory potential in preclinical models. Linalool and bisabolol have been studied for calming and skin-soothing properties, respectively, which may complement CBD’s effects.

Experiential Effects

Consumers consistently describe Suzy Too as clear, calm, and non-sedating at moderate doses. The onset via inhalation is rapid, often within 2–5 minutes, reaching a gentle plateau by 10–15 minutes.

Most report a reduction in bodily tension and a quieting of mental noise without a heady buzz. This makes it a common daytime choice for work, chores, or socializing when one wants balance without impairment.

As doses increase, some users experience a heavier body calm and mild couch-lock, especially in evening contexts. Still, the absence of high THC means the ceiling effect is more about relaxation than euphoria.

Adverse effects are generally mild and infrequent. Dry mouth and dry eyes are the most common, affecting perhaps 20–30% of users depending on environment and hydration.

A minority report lightheadedness or drowsiness at high intake, particularly when combined with alcohol or other sedatives. Starting low and titrating slowly helps users calibrate their personal response.

Compared with THC-dominant flower, Suzy Too’s functional window is wide. Many users find 1–2 inhalations sufficient for a baseline effect, while others prefer 3–5 for deeper body relief without mental fog.

For oral routes, onset usually arrives within 30–90 minutes, with effects lasting 4–8 hours. This extended duration can be useful for steady, all-day support when inhalation isn’t preferred.

Users often pair Suzy Too with tasks requiring patience rather than speed. It suits reading, stretching, gentle exercise, and low-stress creative work where calm focus is the goal.

Potential Medical Uses

CBD-dominant cultivars like Suzy Too are frequently chosen for anxiety, inflammation, and pain modulation. Clinical research on CBD shows mixed but promising signals across several domains, with effect sizes varying by condition and dose.

In seizure disorders such as Dravet and Lennox-Gastaut syndromes, pharmaceutical-grade CBD reduced convulsive seizure frequency by a median 36–44% at 10–20 mg/kg/day in controlled trials. While inhaled flower is not a substitute for standardized products, these data help frame CBD’s neurologic potential.

For anxiety, small trials have shown that a single 300 mg oral CBD dose reduced public speaking-induced anxiety compared with placebo. Real-world patients often use lower repeated doses, such as 25–100 mg/day, and titrate to effect.

Chronic pain evidence for cannabinoids suggests small-to-moderate benefits, with meta-analyses reporting modest reductions in pain intensity. CBD’s role may involve anti-inflammatory pathways and indirect modulation of pain perception.

Beta-caryophyllene, a common Suzy Too terpene, is a selective CB2 agonist with anti-inflammatory and analgesic potential in preclinical models. This could synergize with CBD via the so-called entourage effect, though clinical quantification remains limited.

Sleep benefits appear variable and often dose-dependent. Some users report improved sleep onset with evening use, while others find CBD alerting at low doses and sedating at higher doses.

In musculoskeletal recovery, CBD-rich flower is frequently used for delayed-onset muscle soreness and joint discomfort. Typical inhaled sessions deliver an estimated 10–30 mg CBD depending on technique and potency, with perceived relief in 15–30 minutes.

For inflammatory skin conditions, topical CBD with bisabolol and linalool-rich extracts may support soothing effects. Transdermal absorption varies widely, but many patients prefer topical formats for localized relief without systemic effects.

When dosing with Suzy Too flower, it’s helpful to convert percentages to milligrams to estimate intake. At 15% CBD, a 0.25 g inhalation session contains roughly 37.5 mg CBD, though delivery to the bloodstream is less than 100% due to thermal loss and exhalation.

Drug-drug interactions are a consideration at higher oral CBD doses due to CYP450 metabolism. Patients on narrow-therapeutic-index medications should consult healthcare providers before using high-CBD regimens.

Importantly, individual response varies, so structured self-tracking helps. Logging dose, route, timing, and outcomes for 2–4 weeks allows users to refine an effective, personalized protocol.

Cultivation